financetom
Business
financetom
/
Business
/
Bentley to launch SUV EV in 2026, extend sales of plug-in hybrids to 2035
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bentley to launch SUV EV in 2026, extend sales of plug-in hybrids to 2035
Nov 8, 2024 12:36 AM

LONDON (Reuters) - British luxury carmaker Bentley said on Thursday it will launch its first electric car in 2026 and said it will keep selling plug-in hybrids until 2035, formally abandoning a previous goal of going fully electric by 2030. 

The Volkswagen unit said the first electric Bentley will be a "luxury urban SUV," which will be followed by a new plug-in hybrid or fully-electric model every year over the next decade.

During a press event, CEO Frank-Steffen Walliser said the long-range electric SUV would be more compact than a conventional Bentley, which would make it more suitable for city driving.

Earlier this year Bentley said it might keep selling hybrids beyond 2030, but made that official on Thursday when it said it now aims to be a fully-electric brand by 2035.

But Walliser said that target could shift depending on demand as some global regions are electrifying more slowly.

"Some parts of the world may be even slower than 2035," he said. "We listen carefully to our customers... and what they want to buy."

Others including Volvo Cars have already dropped the ambitious target of going all electric by 2030. 

After a record year in 2022, Bentley posted an 11% drop in vehicle sales for 2023 as high-end consumers across the globe felt the pinch of rising costs and slowing economies.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Compass Therapeutics Begins Dosing Patients in Trial of Potential Treatment for Multiple Cancers
Apr 16, 2024
08:50 AM EDT, 04/16/2024 (MT Newswires) -- Compass Therapeutics ( CMPX ) said Tuesday it dosed its first patient in its phase 1 trial of CTX-8371, a potential cancer treatment. CTX-8371 is a bispecific checkpoint inhibitor. The study includes five ascending doses of CTX-8371 for patients with melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin Lymphoma,...
BRIEF-Rubrik Inc Sees IPO Of Up To 23 Million Shares Of Class A Common Stock- SEC Filing
BRIEF-Rubrik Inc Sees IPO Of Up To 23 Million Shares Of Class A Common Stock- SEC Filing
Apr 16, 2024
April 16 (Reuters) - Microsoft Corp ( MSFT ): * RUBRIK INC: SEES IPO OF UP TO 23 MILLION SHARES OF CLASS A COMMON STOCK- SEC FILING * RUBRIK, INC SAYS CURRENTLY ESTIMATED IPO PRICE PER SHARE WILL BE BETWEEN $28.00 AND $31.00.- SEC FILING * RUBRIK INC-OUTSTANDING SHARES OF CLASS B COMMON STOCK WILL REPRESENT ABOUT 99.3% OF VOTING...
BRIEF-Commvault Announces Acquisition Of Appranix
BRIEF-Commvault Announces Acquisition Of Appranix
Apr 16, 2024
April 16 (Reuters) - Commvault Systems Inc ( CVLT ): * COMMVAULT ANNOUNCES ACQUISITION OF APPRANIX, ACCELERATING AND ADVANCING CYBER RESILIENCE FOR ENTERPRISES GLOBALLY Source text for Eikon: Further company coverage: ...
Asset Entities Files $100 Million Shelf Offering
Asset Entities Files $100 Million Shelf Offering
Apr 16, 2024
08:45 AM EDT, 04/16/2024 (MT Newswires) -- Asset Entities ( ASST ) said Tuesday that it has filed a shelf registration statement for the potential sale of up to $100 million of securities from time to time. The company said the filing covers shares of its Class B common stock, preferred stock, debt securities, warrants, subscription rights and units. Asset...
Copyright 2023-2026 - www.financetom.com All Rights Reserved